AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1890604 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 721 (20, 30, 40, or 50 g orally twice daily for 8 weeks)
Number of subjects: 40
Study 6120718 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 8
Study 6120718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 100 mg
Number of subjects: 8
Study 6120718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 8
Study 6120718 — intervention group
Group type: COMPARATOR
Intervention: Lactose (dummy control)
Number of subjects: 8
Study 30702319 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 134
Study 30702319 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood condition
Number of subjects: 134
Study 27640999 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beer
Number of subjects: 60
Study 27640999 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beer
Number of subjects: 60
Study 23811984 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 55
Study 23811984 — intervention group
Group type: COMPARATOR
Intervention: Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 55
Study 21272824 — intervention group
Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions
Number of subjects: 299
Study 21272824 — intervention group
Group type: COMPARATOR
Intervention: Text-only instructions
Number of subjects: 299
Study 21272824 — intervention group
Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions (low health literacy)
Number of subjects: 299
Study 21272824 — intervention group
Group type: COMPARATOR
Intervention: Text-only instructions (low health literacy)
Number of subjects: 299
Study 21272824 — intervention group
Group type: EXPERIMENTAL
Intervention: Text plus pictogram instructions (adequate health literacy)
Number of subjects: 299
Study 21272824 — intervention group
Group type: COMPARATOR
Intervention: Text-only instructions (adequate health literacy)
Number of subjects: 299
Study 19688312 — intervention group
Group type: EXPERIMENTAL
Intervention: Qufeng Zhidong Recipe (QZR)
Number of subjects: 81
Study 19688312 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus trihexyphenidyl (WM group)
Number of subjects: 81
Study 17578709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 7)
Number of subjects: 31
Study 17578709 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic blockade (n = 8)
Number of subjects: 31
Study 17578709 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (n = 8)
Number of subjects: 31
Study 17578709 — intervention group
Group type: COMPARATOR
Intervention: Mental stress without intervention (n = 8)
Number of subjects: 31
Study 15180776 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Therapy (CBT)
Number of subjects: 88
Study 15180776 — intervention group
Group type: COMPARATOR
Intervention: Group Psychoeducation (PE)
Number of subjects: 88
Study 15180776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and PE
Number of subjects: 88
Study 11497156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF; 6 l/h)
Number of subjects: 11
Study 11497156 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous veno-venous haemofiltration (CVVH; 1 l/h)
Number of subjects: 11
Study 11497156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (HVHF and CVVH)
Number of subjects: 11
Study 11497156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF)
Number of subjects: 11
Study 9228314 — intervention group
Group type: COMPARATOR
Intervention: Interference screw fixation (n = 40)
Number of subjects: 55
Study 9228314 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple fixation (n = 15)
Number of subjects: 55
Study 8221579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin infusion
Number of subjects: 44
Study 8221579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin bolus
Number of subjects: 44
Study 8221579 — intervention group
Group type: EXPERIMENTAL
Intervention: MSK‐NY‐II protocol
Number of subjects: 44
Study 2829323 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment of patients with small cell lung cancer
Number of subjects: 304
Study 2829323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroscopy as the main diagnostic method
Number of subjects: 304
Study 2829323 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomies
Number of subjects: 304
Study 30289006 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic dietary supplement
Number of subjects: 10
Study 30289006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29873709 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved diastolic blood pressure (DBP) <70 mmHg
Number of subjects: 16099
Study 29873709 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved DBP ≥80 mmHg
Number of subjects: 16099
Study 29873709 — intervention group
Group type: COMPARATOR
Intervention: Achieved DBP 70 to <80 mmHg
Number of subjects: 16099
Study 29873709 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved DBP ≥90 mmHg
Number of subjects: 16099
Study 27723225 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 641
Study 27723225 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 641
Study 24915899 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI+PB (panitumumab 3 mg/kg and bevacizumab 3 mg/kg plus FOLFIRI every other week)
Number of subjects: 292
Study 24915899 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (FOLFIRI only)
Number of subjects: 292
Study 22854402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) 50,000 IU/wk for 12 weeks followed by 50,000 IU every other week for 40 weeks
Number of subjects: 46
Study 22854402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20534318 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional chiropractic manipulation (lumbar roll technique with a pisiform contact on the ipsilateral mamillary of L5)
Number of subjects: 20
Study 20534318 — intervention group
Group type: COMPARATOR
Intervention: Sham group (same technique used, but no thrust applied)
Number of subjects: 20
Study 20534318 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional chiropractic manipulation
Number of subjects: 20
Study 18480726 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 0
Study 18480726 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle reconstruction (anteromedial bundle)
Number of subjects: 0
Study 15897728 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (target blood alcohol level of 0.08%)
Number of subjects: 48
Study 15897728 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 48
Study 12689743 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 12689743 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 12689743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Doxazosin and Finasteride
Number of subjects: 0
Study 12689743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10476945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual human interferon-alpha (IFN-alpha) 15 IU
Number of subjects: 124
Study 10476945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual human interferon-alpha (IFN-alpha) 150 IU
Number of subjects: 124
Study 10476945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 8701785 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 22
Study 8701785 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (100 mg on days 5-14 of the menstrual cycle)
Number of subjects: 22
Study 8701785 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 22
Study 8701785 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate
Number of subjects: 22
Study 8701785 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide and Cyproterone acetate
Number of subjects: 22
Study 1676507 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic drugs
Number of subjects: 0
Study 1676507 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 6418100 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 44
Study 6418100 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (700 to 1100 mg/day)
Number of subjects: 44
Study 6418100 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (600 mg/day)
Number of subjects: 44
Study 6418100 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (often associated with Class I antiarrhythmics)
Number of subjects: 44
Study 30684213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting intervention
Number of subjects: 735
Study 30684213 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention
Number of subjects: 735
Study 30684213 — intervention group
Group type: COMPARATOR
Intervention: Control group (screening and referral for behavioral and developmental problems)
Number of subjects: 735
Study 29753661 — intervention group
Group type: COMPARATOR
Intervention: Protocol 1 (P1) with 120 kVp, 180mAs, and 100mL of contrast agent with filtered back‐projection (FBP)
Number of subjects: 60
Study 29753661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (P2) with 80 kVp, 140mAs and 75mL of contrast agent with hybrid iterative reconstruction
Number of subjects: 60
Study 29753661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 3 (P3) with 80 kVp, 140mAs and 75mL of contrast agent with iterative model reconstruction (IMR)
Number of subjects: 60
Study 26902276 — intervention group
Group type: EXPERIMENTAL
Intervention: microRNA‐146a enhancement group
Number of subjects: 12
Study 26902276 — intervention group
Group type: COMPARATOR
Intervention: microRNA‐146a inhibition group
Number of subjects: 12
Study 26902276 — intervention group
Group type: COMPARATOR
Intervention: microRNA control group
Number of subjects: 12
Study 25465181 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium‐90 beta radiotherapy (50 Gy)
Number of subjects: 10
Study 25465181 — intervention group
Group type: COMPARATOR
Intervention: Sham radiotherapy
Number of subjects: 10
Study 21945922 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 0
Study 19073624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 0
Study 19073624 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 17994514 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 38
Study 17994514 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 38
Study 17994514 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C
Number of subjects: 38
Study 15998607 — intervention group
Group type: EXPERIMENTAL
Intervention: ODIN program with postcard reminders (n = 75)
Number of subjects: 255
Study 15998607 — intervention group
Group type: EXPERIMENTAL
Intervention: ODIN program with telephone reminders (n = 80)
Number of subjects: 255
Study 15998607 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control group without access to the ODIN website (n = 100)
Number of subjects: 255
Study 17943671 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted socket
Number of subjects: 9
Study 9614619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 micrograms q.i.d.
Number of subjects: 203
Study 9614619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 micrograms t.i.d.
Number of subjects: 203
Study 9614619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 micrograms q.i.d.
Number of subjects: 203
Study 9614619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 8597466 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 300 mg, orally three times daily for 14 days
Number of subjects: 10
Study 8597466 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule, orally three times daily for 14 days
Number of subjects: 10
Study 2548905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms alpha‐calcoid given orally twice daily (n = 9)
Number of subjects: 30
Study 2548905 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms calcitonin given subcutaneously 30 times (n = 10)
Number of subjects: 30
Study 2548905 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 30
Study 790961 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 30
Study 790961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29206755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 27
Study 29206755 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 27
Study 25724354 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min refresher BLS training
Number of subjects: 112
Study 25724354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no refresher training)
Number of subjects: 112
Study 23769863 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled extra-fine beclomethasone/formoterol (I‐EF‐BDP/F)
Number of subjects: 59
Study 21195292 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 178
Study 21195292 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 178
Study 19395059 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction technique (anterior rhinoscopy and suction)
Number of subjects: 40
Study 19395059 — intervention group
Group type: COMPARATOR
Intervention: Water technique (water poured into kidney tray)
Number of subjects: 40
Study 17175304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based calcineurin inhibitor (CNI)-free regimen (sirolimus 5 mg daily starting postoperative day 3, mycophenolate mofetil 1 gm twice a day, methylprednisolone 500 mg intraoperatively, prednisone 30 mg daily tapered to 10 mg daily at 3 months)
Number of subjects: 0
Study 17175304 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus-based steroid-free regimen (tacrolimus 0.075 mg/kg twice a day, mycophenolate mofetil 1 g twice a day, methylprednisolone 500 mg, 250 mg, and 125 mg from days 0 to 2, then no further steroids)
Number of subjects: 0
Study 12927652 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine 0 mg (placebo)
Number of subjects: 8
Study 12927652 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 8
Study 12927652 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 8
Study 12927652 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 8
Study 12927652 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (all doses)
Number of subjects: 8
Study 10620000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-releasing 'active' patches (approx. 0.4 mg hour‐1 nitroglycerin)
Number of subjects: 20
Study 10620000 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 8620093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy (Zemaphyte) for 8 weeks
Number of subjects: 0
Study 8620093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy (Zemaphyte)
Number of subjects: 0
Study 8620093 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 0
Study 1526863 — intervention group
Group type: EXPERIMENTAL
Intervention: Episcleral plaque radiotherapy (EPRT)
Number of subjects: 85
Study 3919754 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream containing 4% sodium cromoglycate (SCG)
Number of subjects: 46
Study 3919754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29637808 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper cleaning and inspection of slicers (defined as disassembling, cleaning, and sanitizing every 4 hours)
Number of subjects: 298
Study 29637808 — intervention group
Group type: EXPERIMENTAL
Intervention: Slicers being undamaged
Number of subjects: 298
Study 26715234 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min nap (30‐NAP)
Number of subjects: 31
Study 26715234 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min nap (10‐NAP)
Number of subjects: 31
Study 26715234 — intervention group
Group type: COMPARATOR
Intervention: Total sleep deprivation (NO‐NAP)
Number of subjects: 31
Study 24946630 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion applied once a day for 15 days, targeting specific acupoints (Hegu, Quchi, Yanglingquan, Zusanli, Xuehai).
Number of subjects: 68
Study 24946630 — intervention group
Group type: COMPARATOR
Intervention: Medication group used triamcinolone acetonide cream externally and locally, twice a day for 15 days.
Number of subjects: 68
Study 24946630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent treatment for 3 sessions, with hemorheology tests and radioimmunoassays for IL-2, IL-6, IL-10, and TNF-alpha levels.
Number of subjects: 68
Study 23066737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) - 2 × 8 min at 100% peak power output (PPO) with 30 s passive recovery intervals
Number of subjects: 13
Study 23066737 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE) - 22 min at 60% of PPO
Number of subjects: 13
Study 23066737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 13
Study 23066737 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 13
Study 20503055 — intervention group
Group type: EXPERIMENTAL
Intervention: LH/TL+TH (live high/train low plus train high)
Number of subjects: 17
Study 20503055 — intervention group
Group type: COMPARATOR
Intervention: TH (train high)
Number of subjects: 17
Study 20503055 — intervention group
Group type: EXPERIMENTAL
Intervention: LH/TL+TH
Number of subjects: 17
Study 18041396 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Number of subjects: 387
Study 18041396 — intervention group
Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Number of subjects: 387
Study 18041396 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Number of subjects: 387
Study 18041396 — intervention group
Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Number of subjects: 387
Study 16116046 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (160 mg/12.5 mg)
Number of subjects: 482
Study 16116046 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 482
Study 12160563 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100mg)
Number of subjects: 24
Study 12160563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12160563 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-deprived group
Number of subjects: 24
Study 12160563 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study 9576125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (18-month duration)
Number of subjects: 377
Study 8584772 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with fentanyl (10 micrograms/kg initial dose, followed by 5 micrograms/kg/h infusion)
Number of subjects: 14
Study 8584772 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with 60% nitrous oxide in oxygen plus thoracic epidural block with bupivacaine 0.5%
Number of subjects: 14
Study 2236433 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐adrenoceptor blockade (100 mg of atenolol)
Number of subjects: 44
Study 2236433 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 2236433 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol with instruction that heart rate would decrease
Number of subjects: 44
Study 2236433 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol with instruction that did not mention cardiovascular effects
Number of subjects: 44
Study 2236433 — intervention group
Group type: EXPERIMENTAL
Intervention: cardiac aware subjects
Number of subjects: 44
Study 2236433 — intervention group
Group type: EXPERIMENTAL
Intervention: cardiac unaware subjects
Number of subjects: 44
Study 486932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes (1.84 mg standard yield)
Number of subjects: 12
Study 486932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes (0.6 mg standard yield)
Number of subjects: 12
Study 486932 — intervention group
Group type: COMPARATOR
Intervention: Medium-nicotine cigarettes (1.4 mg standard yield)
Number of subjects: 12
Study 486932 — intervention group
Group type: EXPERIMENTAL
Intervention: Puffing behaviour and 24-hour cigarette consumption
Number of subjects: 12
Study 30497684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 750-1000 mg/m2 daily
Number of subjects: 149
Study 30497684 — intervention group
Group type: COMPARATOR
Intervention: Levamisole 2-2.5 mg/kg on alternate days
Number of subjects: 149
Study 30497684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 149
Study 30497684 — intervention group
Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 149
Study 27986549 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y bypass gastroplasty (Bariatric group)
Number of subjects: 60
Study 27986549 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y bypass gastroplasty (Bariatric Diabetic group)
Number of subjects: 60
Study 27986549 — intervention group
Group type: COMPARATOR
Intervention: Clinical treatment (Control group)
Number of subjects: 60